Diabetes patients who take the newest class of diabetes drugs have double the risk of being hospitalized with acute pancreatitis, researchers from Johns Hopkins University School of Medicine, Baltimore, reported in JAMA Internal Medicine. The authors explained that the new forms of sugar-control medications prescribed to diabetes patients are called GLP-1 (glucagon-like peptide-1). Examples of such drugs include sitagliptin (Januvia) and exenatide (Byetta)...
More...
More...